Opinion|Videos|September 24, 2025
Future Treatment of Patients With Alopecia Areata
Panelists discuss how the introduction of Janus kinase (JAK) inhibitor therapies will likely change treatment algorithms for alopecia areata (AA), with insights on how payers should plan for coverage in the coming years and explore the biggest unmet needs for patients with AA and potential improvements in care.
Advertisement
Video content above is prompted by the following:
- McMichael: How do you see treatment algorithms changing with the introduction of JAK inhibitor therapies?
- How do you think payers should anticipate covering AA in the next few years?
- Friedland: What do you see as the biggest unmet needs for patients with AA and how can these be improved in the future?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Beyond the Guidelines Update and Linvoseltamab Approval
September 24th 2025
- Final Takeaways From the Panelists
September 24th 2025
- Optimizing Bispecific Antibody Therapy With Linvoseltamab
September 24th 2025
- Final Thoughts on Arrhythmia Management
September 23rd 2025
- Designing Value-Based Care Programs Around Arrhythmias
September 23rd 2025
- The Utility of Implantable Cardiac Rhythm Monitors
September 23rd 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Administration Flags Potential Link Between Prenatal Acetaminophen Use, Autism
2
Near Low–Income Medicare Beneficiaries Face More Affordability Problems Than Other Income Groups
3
Subtle Brain Changes May Drive Disability in Multiple Sclerosis Beyond Visible Lesions
4
Nicotinamide Reduces New Skin Cancer Risk in Large Veteran Study
5